Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... Ontario, Sept. 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... members of its senior management team will be participating at ... and Chief Executive Officer will make a presentation at the ... London on Thursday, September 15, 2011 at 10:35 a.m. BT ...
... Lifetime Products, Inc. -- a worldwide Utah-based manufacturer ... storage sheds, and lawn and garden products -- announced ... adding a new Health and Wellness product category. ... will feature products like the award-winning Lifetime Tru-Motion™ ...
Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2
(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...
(Date:5/20/2013)... have mapped the significance of heredity for common ... examined whether different forms of the disease share ... ischemic stroke, peripheral arterial disease and atherosclerosis of ... have suffered different types of cardiovascular disease. , ... atherosclerosis of the aorta followed by peripheral arterial ...
(Date:5/20/2013)... Gilman Law LLP, a leading pharmacy ... lawsuits, is troubled by a new study that reveals ... type 2 diabetes drugs are growing. The analysis, ... found that 71 Byetta pancreatic cancer reports had been ... as of June 30, 2012. Overall, Byetta ...
(Date:5/20/2013)... Newport News, VA (PRWEB) May 20, 2013 ... Jeffrey Carlson successfully performed a procedure using SpineFrontier’s FacetFuse ... Fusion Device System. The operation took place on ... Hospital in Newport News, VA. The surgery was ... a 66 year-old, female patient. , Dr. Carlson described ...
(Date:5/20/2013)... The study comprised over 24,000 Finnish subjects and ... revealed that a panel of 28 genetic markers ... coronary heart disease (CHD) (10-year risk ≥20%) over ... is an important preventive strategy for CHD, because ... high-risk group. "The results indicate that genetic markers ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 2Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 3
... ISO 9001 awards showing Spectrum Surgical,s commitment to maintaining the ... ... Stow, OH (PRWEB) April 10, 2009 -- Spectrum Surgical Instruments ... instruments , surgical instrument care products, surgical instrument cleaning brushes, ...
... eyewear to prevent devastating injuriesOKLAHOMA CITY , April 9 ... basketball game his senior year of high school turned into ... played years of hoops without any injuries. But when he ... ended up with a large laceration on his left eyelid ...
... mean an unapproved drug, one of 14 given recent warning, ... 9 (HealthDay News) -- Bowing to the pleas of hospice ... its intent to remove from the market an unapproved liquid ... Throckmorton, deputy director of the FDA,s Center for Drug Evaluation ...
... Therapies Rated More Effective Than Traditional Medical Care ALEXANDRIA, ... top treatment choices of their readers with back pain, ... of more than 14,000 Americans who experience the condition. ... on" therapies outranked treatment by medical specialists and primary ...
... Kensey Nash Corporation (Nasdaq: KNSY ) today ... its third quarter ended March 31, 2009 at 7:30 ... Joe Kaufmann, President and CEO, will be hosting a ... 2009 at 9:00 A.M. Eastern Time. To participate ...
... plan to streamline and modernize administrative and health ... N.Y., April 9 The Coalition ... non-partisan, non-profit service organization dedicated to helping severely ... their families rebuild their lives, issued the following ...
Cached Medicine News:Health News:Spectrum Surgical Instruments Announces: Quality Management System Certification 2Health News:Eye Protection is Essential for Oklahoma Athletes 2Health News:Eye Protection is Essential for Oklahoma Athletes 3Health News:FDA Reverses Stance on Removal of Morphine Painkiller 2Health News:Consumer Reports Survey Shows High Satisfaction for Physical Therapist Treatment of Back Pain 2Health News:Consumer Reports Survey Shows High Satisfaction for Physical Therapist Treatment of Back Pain 3Health News:Kensey Nash Corporation Announces Its Third Quarter 2009 Earnings Release Date and Teleconference 2Health News:Coalition to Salute America's Heroes(TM) Applauds President's Announcement to Create Joint Virtual Lifetime Records 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: